Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Graft Versus Host Disease

Interventions: Drug: carmustine
Drug: melphalan
Drug: etoposide
Drug: cytarabine
Drug: tacrolimus
Drug: methotrexate
Drug: sargramostim
Procedure: transplant

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 4

Registration Number: NCT00006747

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 45 locations

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

Phase 3

Completed

Conditions: Melanoma

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 122

Registration Number: NCT00001296

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

Phase 1

Completed

Conditions: Neoplasm Metastasis
Liver Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001587

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: F-18 Fluorodeoxyglucose
Biological: therapeutic allogeneic lymphocytes
Procedure: Peripheral Blood Stem Cell donation
Drug: cyclophosphamide
Drug: cyclosporine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: prednisone
Drug: sirolimus
Drug: tacrolimus
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Drug: Filgrastim

First Posted Date: 2002-08-16

Last Posted Date: 2017-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00043979

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Procedure: Megadose of CD34 Selected Progenitor Cells
Drug: Melphalan
Drug: Thiotepa
Drug: Fludarabine
Drug: Rabbit ATG

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00038857

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia

Interventions: Drug: Mylotarg
Drug: Fludarabine
Drug: Melphalan
Drug: Anti-thymocyte globulin
Procedure: Stem cell transplant

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT00038831

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Phase 2

Completed

Conditions: Amyloidosis

First Posted Date: 2001-06-06

Last Posted Date: 2008-06-09

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT00017680

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

Phase 1

Completed

Conditions: Colorectal Neoplasm
Liver Neoplasm
Neoplasm Metastasis

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00001576

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy